Publications

Immunotherapy for Advanced Conjunctival Squamous Cell Carcinoma: Treatment Failures

2025

CSCC

In this article, we present a cohort study of patients treated with immunotherapy for advanced conjunctival SCC.

The Evolving Treatment Landscape for CSCC

2025

CSCC

This article examines the evolving role of immunotherapy and dermatologists in CSCC treatment.

Comparing First-Line Immunotherapy in Advanced Melanoma: No Clear Winner?

2025

Melanoma

In this Perspective on Science piece, published in the Journal of Cutaneous Oncology, we reflect on the indirect treatment comparison analysis between RELATIVITY-047 and CheckMate 067 trial data.

Should Ipilimumab Be the New “Standard” for Refractory MCC?

2024

Merkel Cell Carcinoma

Ipilimumab

Ipi/Nivo

In this editorial, published in the Journal of Cutaneous Oncology, we discuss the role of ipilimumab in anti-PD-1 refractory Merkel cell carcinoma. This topic was presented at the Third International Symposium for MCC in Houston, Texas on May 4th 2024.

Tumor-Infiltrating Lymphocyte Therapy Receives FDA Approval

2024

Melanoma

In this editorial, we reflect on the recent approval of the first cellular therapy for melanoma.

Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma

2024

CSCC

In this article, we present a cohort study of patients treated with neoadjuvant cemiplimab or pembrolizumab for advanced cSCC

The Prognostic Value of the Merkel Cell Polyomavirus Serum Antibody Test: A Dual Institutional Observational Study

2024

Merkel Cell Carcinoma

In this preprint, we evaluate the prognostic value of the Merkel Cell Polyomavirus serum antibody test

Perspectives on Medical Aid in Dying: A Multifaceted Ethical Discussion

2024

MAiD

Ethics

In this Perspectives on the Science piece, we reflect on the complex ethical considerations surrounding Medical Aid in Dying, integrating insights from a recent multi-institutional journal club discussion.

Imaging Surveillance for Stage III Melanoma: Should We Be Stalkers or Casual Observers?

2024

Melanoma

In this Perspectives on the Science piece, we reflect on the role of surveillance imaging for patients with high-risk melanoma.

A Closer Look: Evaluating Mohs Surgery’s Role in the Treatment of Invasive Melanoma of the Head and Neck

2024

In this Perspectives on the Science piece, we reflect on the implications of the recently conducted multicenter study on the treatment of invasive head and neck melanoma using Mohs micrographic surgery.

Adjuvant anti-PD-1 for Merkel Cell Carcinoma: Ready for the Clinic?

2023

In this Perspectives on the Science piece we reflect on the recently published ADMEC-O trial.

To Screen or Not To Screen, That is the Question

2023

In this Perspectives on the Science piece we reflect on the impact of the recent USPSTF recommendation statement on skin cancer screening.

Immunotherapy and Cardiovascular Health - A Cause for Concern?

2023

In this Perspectives on the Science piece we reflect on the impact of ‘Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque’ by Drobni et al.

Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?

2023

Melanoma

Neoadjuvant

Adjvuant

In this Perspectives on the Science piece we reflect on the impact of the recently published SWOG S1801 trial.

Skin Cancer Chemoprevention for Transplant Recipients - The Search Continues

2023

CSCC

In this Perspectives on the Science piece, we reflect on the impact of the recently published ONTRANS trial.

Surgical Factors Affecting Regionally Metastatic Cutaneous Squamous Cell Carcinoma to the Parotid Gland

2023

CSCC

Understanding the impact of surgical treatment on regionally metastatic cutaneous squamous cell carcinoma (cSCC) is important as treatment paradigms shift with the introduction of immune checkpoint inhibitors. Herein, we aim to describe surgical impact on outcomes for regionally metastatic cSCC

Lacking Overall IMspiration for Triplet Therapy in Melanoma? A Review of the Interim Analysis of IMspire150.

2023

Melanoma

In this Perspectives on the Science piece, we reflect on the impact of the recently published article by Ascierto et al. in Lancet Oncology that provides interim results from IMspire150.

Targeting TBK1 to overcome resistance to cancer immunotherapy

2023

We demonstrate that targeting TBK1 is a novel and effective strategy to overcome resistance to cancer immunotherapy.

Therapy with oncolytic viruses: progress and challenges

2023

We review the available data and provide guidance on optimizing the use of oncolytic viruses in clinical practice.

Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma: Ready for Prime Time?

2023

Melanoma

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma”.

StoryboardR - An R Package and Shiny Application Designed to Visualize Real-World Data From Clinical Patient Registries

2023

Clinical Informatics

R

REDCap

We created StoryboardR, an R package and Shiny application facilitates the data visualization of real-world data from tumor registries captured in REDCap^®.

Neoadjuvant Nivo/Rela for Resectable Melanoma

2022

Melanoma

Neoadjuvant

Nivo/Rela

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Ipi/Nivo for Advanced MCC

2022

Merkel Cell Carcinoma

Ipi/Nivo

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology, we reflect on the impact of the recently published article “Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel cell carcinoma - A Randomised, Open Label, Phase 2 Trial”.

Neoadjuvant ICI for Resectable CSCC

2022

Squamous Cell Carcinoma

Neoadjuvant

In this Perspectives on the Science piece, published in the Journal of Cutaneous Oncology we reflect on the impact of the recently published article Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network

2022

We present the results of a clinical pilot to standardize precision oncology workflows. This was published in The Oncologist in November 2022.